Pharvaris shares are trading higher after the FDA lifted clinical hold from Investigational new drug application for deucrictibant for hereditary angioedema
Portfolio Pulse from Benzinga Newsdesk
The FDA has lifted the clinical hold on Pharvaris' Investigational New Drug application for deucrictibant, a treatment for hereditary angioedema, causing the company's shares to trade higher.
June 26, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pharvaris shares are trading higher after the FDA lifted the clinical hold on the company's Investigational New Drug application for deucrictibant, a treatment for hereditary angioedema.
The FDA lifting the clinical hold on Pharvaris' IND application for deucrictibant is a positive development for the company, as it allows them to proceed with clinical trials and potentially bring the drug to market. This news is likely to boost investor confidence in the company's prospects, leading to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100